202 related articles for article (PubMed ID: 15662289)
1. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment.
Mayer MD; Khosravan R; Vernillet L; Wu JT; Joseph-Ridge N; Mulford DJ
Am J Ther; 2005; 12(1):22-34. PubMed ID: 15662289
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects.
Khosravan R; Grabowski BA; Wu JT; Joseph-Ridge N; Vernillet L
Clin Pharmacokinet; 2006; 45(8):821-41. PubMed ID: 16884320
[TBL] [Abstract][Full Text] [Related]
3. A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: pharmacokinetic and pharmacodynamic study.
Hosoya T; Ohno I
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S27-34. PubMed ID: 21654267
[TBL] [Abstract][Full Text] [Related]
4. The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.
Khosravan R; Kukulka MJ; Wu JT; Joseph-Ridge N; Vernillet L
J Clin Pharmacol; 2008 Sep; 48(9):1014-24. PubMed ID: 18635756
[TBL] [Abstract][Full Text] [Related]
5. The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.
Khosravan R; Grabowski BA; Mayer MD; Wu JT; Joseph-Ridge N; Vernillet L
J Clin Pharmacol; 2006 Jan; 46(1):88-102. PubMed ID: 16397288
[TBL] [Abstract][Full Text] [Related]
6. Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase.
Grabowski B; Khosravan R; Wu JT; Vernillet L; Lademacher C
Br J Clin Pharmacol; 2010 Jul; 70(1):57-64. PubMed ID: 20642548
[TBL] [Abstract][Full Text] [Related]
7. Metabolism and excretion of [14C] febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, in healthy male subjects.
Grabowski BA; Khosravan R; Vernillet L; Mulford DJ
J Clin Pharmacol; 2011 Feb; 51(2):189-201. PubMed ID: 20354234
[TBL] [Abstract][Full Text] [Related]
8. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Ernst ME; Fravel MA
Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
[TBL] [Abstract][Full Text] [Related]
9. Febuxostat for management of tumor lysis syndrome including its effects on levels of purine metabolites in patients with hematological malignancies - a single institution's, pharmacokinetic and pilot prospective study.
Takai M; Yamauchi T; Ookura M; Matsuda Y; Tai K; Kishi S; Yoshida A; Iwasaki H; Nakamura T; Ueda T
Anticancer Res; 2014 Dec; 34(12):7287-96. PubMed ID: 25503162
[TBL] [Abstract][Full Text] [Related]
10. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers.
Becker MA; Kisicki J; Khosravan R; Wu J; Mulford D; Hunt B; MacDonald P; Joseph-Ridge N
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1111-6. PubMed ID: 15571211
[TBL] [Abstract][Full Text] [Related]
11. Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout.
Schumacher HR
Expert Opin Investig Drugs; 2005 Jul; 14(7):893-903. PubMed ID: 16022578
[TBL] [Abstract][Full Text] [Related]
12. PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment.
Hoshide S; Takahashi Y; Ishikawa T; Kubo J; Tsuchimoto M; Komoriya K; Ohno I; Hosoya T
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1117-8. PubMed ID: 15571212
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects.
Yoon S; Shin D; Lee H; Jang IJ; Yu KS
Drug Des Devel Ther; 2015; 9():5033-49. PubMed ID: 26357467
[TBL] [Abstract][Full Text] [Related]
14. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Devineni D; Curtin CR; Marbury TC; Smith W; Vaccaro N; Wexler D; Vandebosch A; Rusch S; Stieltjes H; Wajs E
Clin Ther; 2015 Mar; 37(3):610-628.e4. PubMed ID: 25659911
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment.
Martin DE; Chapelsky MC; Ilson B; Tenero D; Boike SC; Zariffa N; Jorkasky DK
J Clin Pharmacol; 1998 Feb; 38(2):129-37. PubMed ID: 9549643
[TBL] [Abstract][Full Text] [Related]
16. Effects of renal function on pharmacokinetics and pharmacodynamics of lesinurad in adult volunteers.
Gillen M; Valdez S; Zhou D; Kerr B; Lee CA; Shen Z
Drug Des Devel Ther; 2016; 10():3555-3562. PubMed ID: 27843295
[TBL] [Abstract][Full Text] [Related]
17. Comparison of pharmacokinetics and uric acid lowering effect between two different strength febuxostat formulations (80 mg vs. 40 mg) in healthy subjects.
Kim KA; Park JY
Int J Clin Pharmacol Ther; 2015 Aug; 53(8):667-73. PubMed ID: 25997544
[TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function.
Aweeka F; Jayesekara D; Horton M; Swan S; Lambrecht L; Wilner KD; Sherwood J; Anziano RJ; Smolarek TA; Turncliff RZ
Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):27S-33S. PubMed ID: 10771451
[TBL] [Abstract][Full Text] [Related]
19. Effect of renal impairment on the pharmacokinetics of intravenous zanamivir.
Cass LM; Efthymiopoulos C; Marsh J; Bye A
Clin Pharmacokinet; 1999; 36 Suppl 1():13-9. PubMed ID: 10429836
[TBL] [Abstract][Full Text] [Related]
20. Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S19-26. PubMed ID: 21654266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
